Bennet-Led Bill, Included in Bipartisan Legislation to Reauthorize FDA User Fee Programs, Would Ensure Diagnostic Testing Protects Patient Safety, Keeps Pace With Medical Innovation
Washington, D.C. — Today, Colorado U.S. Senator Michael Bennet applauded passage of his Verifying Accurate Leading-Edge IVCT Development (VALID) Act out of the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee. Bennet and U.S. Senator Richard Burr’s (R-N.C.) bipartisan legislation passed as a part of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, which will reauthorize the U.S. Food and Drug Administration’s (FDA) user fee programs.
“I’m pleased that my bill with Senator Burr to establish a modern diagnostic testing regulatory process passed out of committee today as a part of the Senate FDA User Fees reauthorization bill,” said Bennet. “The COVID-19 pandemic has made clear the importance of reliable tests for patient safety, and the VALID Act would establish a new regulatory structure to ensure that accurate and high-quality diagnostic tests are available for Coloradans, especially those with rare diseases and conditions. We’re one step closer to getting this done for Colorado patients.”
In 2018, Bennet introduced a version of the VALID Act with U.S. Senator Orrin Hatch (R-Utah) before reintroducing it with Burr in June 2021. The VALID Act would create a new regulatory framework for the review and approval of diagnostic tests to accelerate the development of new technologies, protect public health, and ensure Americans can rely on the test results they receive.